Edition:
United States

Medtronic PLC (MDT)

MDT on New York Consolidated

85.09USD
26 May 2017
Change (% chg)

$-0.49 (-0.57%)
Prev Close
$85.58
Open
$85.58
Day's High
$85.82
Day's Low
$84.60
Volume
4,796,850
Avg. Vol
4,546,492
52-wk High
$89.27
52-wk Low
$69.35

Select another date:

Thu, May 25 2017

Medtronic's focus on surgical products fuels profit beat

Medtronic Plc 's fourth-quarter profit topped analysts' estimates as the world's largest standalone medical device maker saw increased demand across almost all of its businesses, including its minimally invasive therapies.

UPDATE 3-Medtronic's focus on surgical products fuels profit beat

* Minimally invasive therapies unit sales up 6 pct (Adds details, analysts' comments)

Medtronic reports 5.3 pct rise in quarterly profit

May 25 Medtronic Plc, the world's largest standalone medical device maker, reported a 5.3 percent rise in quarterly profit on Thursday, driven by higher sales in all of its businesses.

BRIEF-QT Vascular updates on potential transaction with Medtronic

* Negotiations in relation to possible transaction(s) involving company's coronary product(s)

BRIEF-Medtronic Resolute Onyx 2.0 mm clinical study meets primary endpoint

* Medtronic resolute onyx(tm) 2.0 mm clinical study meets primary endpoint in extra-small vessels at one-year Source text for Eikon: Further company coverage:

BRIEF-QT Vascular enters into asset purchase option agreement with Medtronic

* upon exercise of option by medtronic and closing , medtronic shall pay to sellers purchase consideration of us$28 million

BRIEF-Medtronic receives FDA approval for MR-conditional quadripolar cardiac resynchronization therapy-pacemakers

* Medtronic first to receive FDA approval for MR-conditional quadripolar cardiac resynchronization therapy-pacemakers

BRIEF-Medtronic expands pain therapies portfolio with the launch of Osteocool RF ablation system

* Medtronic expands pain therapies portfolio with the launch of Osteocool RF ablation system Source text for Eikon: Further company coverage:

BRIEF-Medtronic announces outcomes from VeClose clinical trial, ‍WAVES study​

* New Medtronic data demonstrate clinical and quality of life benefits for VenaSeal closure system in venous reflux disease patients

BRIEF-Medtronic drug-coated balloon demonstrates consistent results

* Medtronic drug-coated balloon (DCB) demonstrates consistent results in two new analyses of complex pad patients

Select another date:

More From Around the Web